GLP-1 medications are usually considered for individuals with a BMI of 30+ , or 27+ with related conditions , so eligibility matters from the start
Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: a retrospective cohort study
Rise of GLP-1s raise affordability questions By the numbers: According to the studys findings, the use of GLP-1 medications among U.S
Anti-aging: Can improve skin firmness, elasticity, and clarity, potentially reducing fine lines and wrinkles
As Alzheimers pathology develops, levels of p-tau217 rise dramatically (4)
This underutilization is due to a variety of barriers at the patient, clinician, and organizational levels